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prostatic obstruction concluded negatively about photoselective
vaporization of the prostate (PVP), and the 2010 National Institute
for Health and Care Excellence guidance caused several UK institu-
tions to abandon PVP. Objective: To reassess the costs and effects of
PVP versus transurethral resection of the prostate (TURP) on the basis
of most recent data. Methods: The same model was used as in 2008.
Transition probabilities were estimated using a Bayesian approach
updating the 2008 estimates with data from two meta-analyses and
data from GOLIATH, the latest and largest trial comparing PVP with
TURP. Utility estimates were from the 2008 assessment, and estimates
of resource utilization and costs were updated. Effectiveness was
measured in quality-adjusted life-years gained, and costs are in UK
pounds. The balance between costs and effects was addressed by
multivariate sensitivity analysis. Results: If the 2010 National Insti-
tute for Health and Care Excellence analysis would have updated the
cost-effectiveness analysis with ﬁgures from its own meta-analysis, itee front matter Copyright & 2015, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/4.0/).http://dx.doi.org/
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.would have estimated the change in quality-adjusted life-years at
0.01 (95% conﬁdence interval [CI] 0.05 to 0.01) instead of at 0.11
(95% CI 0.31 to 0.01) as in the 2008 analysis. The GOLIATH estimate
of 0.01 (95% CI 0.07 to 0.02) strengthens the conclusion of near
equivalence. Estimates of additional costs vary from £491 (£21£1286)
in 2008 to £111 (£315 to £595) for 2010 and to £109 (£204 to £504) for
GOLIATH. PVP becomes cost saving if more than 32% can be carried
out as a day case in the United Kingdom. Conclusions: The available
evidence indicates that PVP can be a cost-effective alternative for
TURP in a potentially broad group of patients.
Keywords: benign prostatic obstruction, cost effectiveness analysis,
NICE guidance, health care, United Kingdom.
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Benign prostatic obstruction (BPO) leading to bothersome lower
urinary tract symptoms negatively affects quality of life in older
men. Prevalence is more than 50% in men in their sixties,
increasing to 90% for those older than 80 years [1,2]. Men aged
40 to 50 years who present with lower urinary tract symptoms
have a 20% to 30% chance of ever undergoing a prostatectomy [3].
Typically, medical therapy is the ﬁrst-line treatment offered.
When this fails, standard treatment is transurethral resection of
the prostate (TURP). TURP requires anesthesia and 2- to 4-day
hospitalization and is associated with several potential compli-
cations including transurethral resection syndrome (o1.1%),
blood transfusion (2.9%–8.4%), urethral stricture (3.8%), bladderneck contracture (4.7%), retrograde ejaculation (65.4%), impotence
(6.5%), urinary incontinence (2.2%), and mortality (0.1%–0.25%) [4].
Consequently, alternative procedures were developed in an
attempt to minimize invasiveness, reduce complications, and
shorten recovery times. In 2008, the National Institute for Health
Research commissioned a health technology assessment (HTA)
comparing alternative therapies with TURP. The assessment
concluded that “In the absence of strong evidence in favor of
newer therapies, TURP remains both clinically effective and cost-
effective. The use of minimally invasive technologies in the NHS
is not appropriate until a more effective and/or less costly
technology is available” [5]. Moreover, it recommended that “A
well conducted head-to-head trial of treatment strategies ….
would be most desirable to establish the gold standard. Such aociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 7 6 – 3 8 6 377trial should take prostate size into account and should include
direct measures of utility” [5].
Laser vaporization of the prostate was one of the innovative
therapies included in the 2008 assessment. The assessment
pooled data from multiple laser systems, delivering energy from
different light spectrums, resulting in different methods of vapor-
izing obstructing prostate tissue. A publication summarizing the
cost-effectiveness analysis stated, “Potassium titanyl phosphate
laser vaporisation was unlikely to be cost effective … which
argues against its unrestricted use until further evidence of
effectiveness and cost reduction is obtained” [6]. The National
Institute for Health and Care Excellence (NICE) guidance that
followed in 2010 recommended to “only consider offering laser
vaporisation techniques …. as part of a randomised controlled
trial that compares these techniques with TURP.” Strangely,
although NICE reevaluated the evidence base, eliminating a
Dutch study [7] with an atypical rate of incontinence, it did not
reevaluate the cost-effectiveness, thereby never noticing the
consequences of deleting this Dutch study from the evidence.
As a result, utilization of laser vaporization decreased dramati-
cally in the United Kingdom.
Photoselective vaporization (PVP) was one of the systems
adding to the evidence base by one study [8]. Since 2008, two
signiﬁcant technological improvements in PVP were introduced:
increased laser power and an improved laser delivery system for
rapid and hemostatic treatment of large prostate glands. In
addition, the largest randomized controlled trial (RCT) comparing
PVP with TURP, the GOLIATH trial—a noninferiority study of men
with lower urinary tract symptoms due to BPO—was initiated [9].
The clinical manuscript summarizes the results by saying that
The study demonstrated the non-inferiority of XPS to TURP
for IPSS, Qmax (maximum ﬂow rate) and complication-free
proportion. PV and PVR were comparable between groups.
Time until stable health status, length of catheterisation, and
length of hospital stay were superior with XPS (p o 0.001).
Early re-intervention rate within 30 d was three times higher
after TURP (p ¼ 0.025); however, the overall postoperative re-
intervention rates were not signiﬁcantly different between
treatment arms. Conclusions: XPS was shown to be non-
inferior (comparable) to TURP in terms of IPSS, Qmax, and
proportion of patients free of complications. XPS results in a
lower rate of early reinterventions but has a similar rate after
6 mo. [9]
However, it may be noted that the difference in the Interna-
tional Prostate Symptom Score is borderline, signiﬁcantly in favor
of TURP, and that the secondary end points—concerning symp-
toms—are also, albeit nonsigniﬁcantly, in favor of TURP. So, there
may a trade-off between efﬁcacy, safety, convenience, and costs
and each aspect may be associated with its own “value.” In 2008,
the difﬁculty to bring together the various risks, disutilities, and
costs was acknowledged by the use of a cost-effectiveness model
that included all these in a structured and transparent way. The
model, a Markov-type model, included parameters concerning
baseline risks, probability of success, and incidence of transient
and permanent adverse effects as well as estimates of costs and
disutilities due to adverse effects. Estimates of efﬁcacy and
adverse effects were based on meta-analyses. Now, more RCTs
are available, not only GOLIATH using the 180-W system but also
four trials using the 120-W system and four that used the 80-W
laser system, as included in a 2012 meta-analysis [10].
The emerging situation seems tailormade for a Bayesian
approach. Bayesian statistics build on the idea of continuously
updating the relevant estimates by combining prior information
with new data [11]. The combination of priors with new data
leads to posterior distributions in which means or medians canbe used as point estimates and 95% credible intervals can be used
to indicate the degree of remaining uncertainty. Within this, the
posterior distributions of today become the prior distributions of
tomorrow. The 2008 data can be used to formulate a “prior”
distribution, and to combine this with the “data” from subse-
quent studies to estimate the current, most up-to-date “poste-
rior” distributions of costs, effects, and the balance between costs
and effects. The expectation may be that such stepwise Bayesian
approach will iterate to less and less uncertainty. This applies,
however, only to a rather stable situation. Medical technologies
such as PVP and TURP continuously evolve, and as such prior
distributions may reﬂect only outdated information. One might
expect improvements, especially in the active treatment arm but
also in the control arm. In addition, one might expect surgeons to
broaden the indication, given the increased safety and efﬁcacy.
Expert elicitation might be used to capture such phenomena
reﬂected by the inclusion of parameters indicating the improve-
ments in technology and case mix. The analysis presented here
does not go that far. The Bayesian case, building on former
evidence is the one, rather conservative extreme, building the
evidence in time, without acknowledging any progress by weigh-
ing newer data more heavily. The other extreme is to use
separate chunks of evidence as used in previous analyses and
to add the data from the GOLIATH study as another separate
chunk. Both approaches will lead to updated estimates of costs
and effects, and together they are a source of information for an
updated decision of the position of laser therapy for benign
prostatic hyperplasia (BPH).Methods
The Model
The parameters and model used in the 2008 HTA form the basis
of this analysis [5]. The model is a state transition Markov-type
model with a lifelong time horizon in which patients, after initial
treatment, are categorized in mutually exclusive states guided by
their urinary symptoms and whether or not they have incon-
tinence symptoms (Fig. 1). In line with the 2008 model, reopera-
tions may be carried out in case of insufﬁcient relief but not in
case of persistent urinary incontinence. Also, the use of alpha-
blockers and ﬁve alpha reductase inhibitors in case of failure is
not included except after two treatment failures. Mortality is
assumed not to be affected by treatment, and age-speciﬁc
population mortality rates for English men are used.
The 2008 model was programmed in TreeAge. To gain insight
and to optimize computer time, it was reprogrammed in Excel.
The only estimates that were not taken from the original model,
keeping the structure and most estimates identical, concerned
procedural cost parameters, unit cost estimates, and estimates
concerning efﬁcacy and safety. The latter estimates were
obtained by reading the efﬁcacy and safety data—as reported in
Appendix 1—into R and calling WinBugs from R. Multivariate
sensitivity analysis was carried out on the basis of 1000 random
draws using a macro in Excel.
In case of discrepancies between the publication and the
TreeAge program, the TreeAge program was taken as reference.
For example, the 2008 TreeAge model used a meta-analysis of all
TURP data for the estimate of the incidence of adverse effects,
leading to, among others, a baseline rate of urinary incontinence
of 151/1935 (¼7.8%). This is contrary to the estimate of 0.03 as
published in Table 30. Similarly, with respect to the utilities,
estimates from the TreeAge code were used (where the 95%
conﬁdence intervals are surrounding the point estimates, as one
would expect.) Another change is that in the rare case of multiple
adverse effects, utilities were estimated by multiplication.
Fig. 1 – Model. BPO, benign prostatic obstruction. (Color version of ﬁgure appears online.)
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estimated on the basis of the number of patients with a 10% or
more/less than 10% decrease in the International Prostate Symp-
tom Score. To derive this probability, patient-level data are
needed or at least an estimate of the variance of the mean
change. In 2008, an estimate of the latter was obtained from a
cohort of patients with TURP and in combination with some
assumption results that showed face validity were obtained. This
was not the case when applying the same method to the later
data, potentially due to differences in variance. In 2008, as an
alternative, within the sensitivity analysis, success was esti-
mated using the percentage of patients undergoing reoperation.
For this, no additional data are needed nor any assumptions.
Here, the latter approach is chosen to deﬁne the measure of
efﬁcacy.
The only permanent complication within the model is the
occurrence of persistent urinary incontinence. This was assumed
to be known at 3 months after initial treatment and within the
model this is the same period when a number of transient
complications may occur: the transurethral resection syndrome,
acute urinary retention, urinary tract infection, strictures/bladder
neck contracture, and blood transfusion. Complications are
captured by one-time probabilities associated with the initial
procedure. The probability of movement from one state to
another is captured by transition probabilities, which reﬂect the
probability of a non–procedure-related-relapse initiating repeat
treatment. With subsequent treatments, a decrease in efﬁcacy is
taken into account.
A health care perspective is taken. Costs concern those related
to the procedure, the length of hospital stay, and the treatment of
complications.
Effectiveness is expressed in terms of the percentage of
patients without complications and without repeat procedures,
the number of incontinent patients at 6 or 12 months, and
the expected number of quality-adjusted life-years (QALYs).
Both total costs and QALYs are presented with a discount rate
of 3.5%.The time horizon is lifelong. The primary efﬁcacy outcome of the
analysis is QALYs. These are estimated by multiplying the duration
in each health state with its corresponding utility value. The short-
time QALY losses associated with transient adverse effects are
included in the valuation of the ﬁrst 3 months after the procedure.
All analyses compared two strategies: one that starts with
TURP and one that starts with PVP, both followed by TURP when
indicated.
Data Sources
Data are used from three published meta-analyses and from
GOLIATH. All data compare laser vaporization techniques to
TURP. The ﬁrst two sources, analyzing multiple laser vaporization
technologies, are meta-analyses included in the 2008 HTA and
the 2010 NICE guidance [5,12]. The data underlying a 2012 meta-
analysis comprise the third source [13–19]. One-year data from
GOLIATH, using 180-W technology, are the fourth source [9].
Importantly, 2008 and 2010 meta-analyses differ in that the
latter included a study published in 2008 [13] and most impor-
tantly excluded a Dutch study from 2003 [7]. This changed the
estimated risk ratio for incontinence from 2.24 (1.03–4.88) to 0.90
(0.26–3.15).
As in 2008, procedure costs are based on reference cost,
Personal Social Services Unit (PSSRU), and British National For-
mulary (BNF) estimates (in 2013 pounds). A weighted average of
the number of day cases and inpatient cases was used, with
weights obtained from the GOLIATH study. The difference in
length of stay and the use of ﬁbers for PVP and loops for TURP
was also estimated on the basis of GOLIATH.
Comparisons
Five sets of estimates of baseline and transition probabilities
were used to estimate the costs and effects of PVP versus TURP:1. Those based on the 2008 meta-analysis and used in the 2008
cost-effectiveness model estimates;
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 7 6 – 3 8 6 3792. Those based on the 2010 meta-analysis (but never used in a
cost-effectiveness analysis);3. Posterior estimates of 120-W systems with a prior based on
the 2010 and 2012 80-W systems;4. GOLIATH with uninformed prior distributions; and
5. GOLIATH with the posterior from 3) as prior information.
All data are included in the Appendix.
Within the analysis, attention was drawn to the fact that
patients with PVP may be treated in a day-case setting, which is a
rare possibility for patients with TURP. The analysis estimates
the percentage of day-case procedures required, from which cost
savings can be expected.
Statistical Analysis
In 2008, baseline risks were estimated using beta distributions,
with risk ratios estimated using a ﬁxed-effects meta-analysis.
Here, random-effect models were used for all risk ratios using
programs fromWarn et al. [20] who describe a Bayesian approach
to a random-effects meta-analysis for binary outcomes. Initial
risks after TURP were estimated separately. The noninformative
approach used a beta distribution for the initial risk, assuming a
[0,1] uniform prior and a binomial distribution for the data. This
implies that in case of zero events no continuity correction is
needed as was the case in 2008. In the informed analysis, the
prior is the former posterior. Within the estimation a random
component was included (as in a random-effects analysis). The
latter was to reﬂect the additional variation—and uncertainty—
that results from the potential difference in surgical skills with
respect to TURP.
The distribution of costs and effects was estimated using
probabilistic sensitivity analysis drawing at random from the
uncertainty distributions that are deﬁned surrounding all input
parameters.
Estimates of costs and effects are presented in cost-
effectiveness planes and summarized in terms of the probability
to be more or less effective, more or less costly, and the
probability that the cost-effectiveness ratio is less than (when
effects are positive) or more than £20,000 (when effects are
negative). The same results are presented for a cost-
effectiveness ratio of £30,000.Results
The estimates concerning baseline risk and risk ratios are
presented in Table 1.
The difference between the baseline risks as estimated in 2008
and 2010 is explained by the fact that the 2008 estimates are
based on all TURP trials, including those comparing with other
treatments, whereas the 2010 estimates are based on TURP trials
only in comparison with laser therapy. For example, considering
the incidence of incontinence, if only trials comparing PVP versus
TURP would have been used, an estimate of 2.46% would have
resulted.
The differences between the 2008 and 2010 meta-analyses
with respect to risk ratios are mainly explained by differences in
the inclusion and exclusion of trails. The 2010 analysis—being 2
years later—included some more recent trials, and it also
included one older trial and excluded data from other trials that
were included in the 2008 analysis. Details are included in the
Appendix in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2015.04.002.
It was expected that the informed analyses would lead to less
uncertainty. Surprisingly, it is not seen in baseline risk rates,
where the variability in the various trials lead to only smalldifferences in uncertainty between the informed and uninformed
GOLIATH analysis. Substantial differences are found in the risk
ratios, most notably where laser therapy is shown to decrease the
occurrence to almost zero. Attention may be drawn to the risk of
the transurethral resection syndrome, which is nonexistent after
laser therapy. In the uninformed GOLIATH analysis, it is esti-
mated at 0.64, which is due to the zero event correction. In the
informed analysis, it is equal to 0.02. In this respect, the Bayesian
approach offers a deﬁnite advantage, given that the transurethral
resection syndrome can only be the result of a crossover and in
the informed analysis this is learned in time. Moreover, instead
of a noninformative prior, as used here, an informed prior might
have been used, narrowing the uncertainty even further.
Table 2 presents updated UK estimates concerning resource
utilization and unit costs as well as some additional parameters.
Among the latter are estimates for quality-of-life parameters
taken from the 2008 HTA as well as estimates for the probability
of requiring TURP after urinary retention, the decrease in efﬁcacy
at subsequent procedures, and the probability of a relapse. All
estimates are associated with uncertainty distributions, which
are used in the multivariate sensitivity analysis.
Figure 2 presents the days of hospitalization in both arms of
GOLIATH. The average difference is 1.15 days. This is shorter than
the 1.97 days obtained by taking a weighted average of the ﬁgures
reported in the trials included in the 2012 meta-analysis [10].
Table 3 presents estimates of costs and effects within a
lifetime horizon. The 2008 analysis shows a difference of 0.11
QALYs and a 95% upper uncertainty margin of 0.01, which might
be labeled as a signiﬁcantly worse outcome. Similarly, one may
label costs as signiﬁcantly higher, with the lower bound of the
95% credible interval being equal to £21. So, one ﬁnds a signiﬁ-
cantly worse outcome with a signiﬁcant increase in costs and
therefore, the conclusion drawn in 2008 seemed justiﬁed. The
conclusion in the BMJ saying that “The use of … laser vapor-
isation incurred higher costs and was less effective” and “ﬁndings
were unchanged by wide ranging sensitivity analyses” was based
on this. This is based, however, on a rather unrealistic approx-
imate 18% rate of incontinence after PVP. In contrast, the 2010
and later analyses show that credible intervals for QALY and cost
difference cross zero, suggesting with much less certainty that
those differences are due to differences in treatment. It may be
speculated that this would have led to another conclusion.
Figure 3 shows that all density of costs and effects is in the
quadrant of higher costs and less efﬁcacy driven particularly by
the 2008 incontinence estimates. It also shows that an updated
cost analysis using the 2010 meta-analysis would have shifted
estimates to the right. One may still not conclude that this
implies equivalence, but such a picture may—when considering
additional arguments such as convenience—lead to a different
conclusion.
Figure 4 indicates the changing levels of uncertainty sur-
rounding costs and effects as new evidence becomes available,
starting from the 2010 meta-analysis. It appears that GOLIATH
has not shifted the results toward more efﬁcacy or lower costs. It
also appears that the decreased uncertainty of the informed
analysis has not resulted in a spectacular change in overall
uncertainty when compared with the uninformed analysis.
Table 4 presents percentages in the four quadrants of the cost-
effectiveness plane. With the 2008 estimates, the probability of
cost-effectiveness being in an acceptable range (cost-effectiveness
ratioo£20,000 or both more expensive and less costly) is very low,
0.065%, and the decision that it is not cost-effective is straightfor-
ward. For 2010, it is estimated at 28% and when using results from
the 120-W technology; informed by the 80-W technology, an
estimate of 52% results. This decreases again to about 30% when
using the informed GOLIATH analysis. Using a higher threshold of
£30,000 does not alter the results substantially.
Table 1 – Baseline risks and risk ratios.
Baseline risks 2008 meta-analysis 2009 meta-analysis 120 W informed by 80 W GOLIATH GOLIATH informed
Point
estimate
(%)
95% credible
interval
(%)
Point
estimate
(%)
95% credible
interval
(%)
Point
estimate
(%)
95% credible
interval
(%)
Point
estimate
(%)
95% credible
interval
(%)
Point
estimate
(%)
95% credible
interval
(%)
Reoperation 4.56 3.56–5.23 4.72 1.73–10.43 2.65 1.00–5.76 3.30 1.14–7.56 3.01 1.40–5.68
Incontinence 7.80 6.17–8.39 1.12 0.22–3.50 1.06 0.24–3.08 2.99 1.00–6.99 2.60 1.07–5.35
AUR 4.42 3.34–5.23 1.58 0.48–3.90 4.63 1.42–11.39 9.69 5.63–15.60 8.53 5.08–13.44
BNC 6.25 4.95–6.88 6.26 3.48–10.40 7.46 2.71–16.58 6.80 3.43–12.16 7.23 4.09–11.88
Blood transfusion 8.10 6.54–8.51 3.59 0.95–9.58 4.68 1.57–10.94 1.59 0.28–5.16 2.39 0.94–5.06
TUR syndrome 2.04 1.27–2.88 6.26 3.48–10.40 2.65 0.56–7.92 0.37 0.00–2.52 1.01 0.27–2.67
UTI 7.17 5.54–7.94 7.45 2.59–17.03 7.03 2.72–15.05 10.65 6.27–16.97 10.60 6.69–15.99
Risk ratios 2008 meta-analysis 2009 meta-analysis 120 W informed by 80 W GOLIATH GOLIATH informed
Point
estimate
95% credible
interval
Point
estimate
95% credible
interval
Point
estimate
95% credible
interval
Point
estimate
95% credible
interval
Point
estimate
95% credible
interval
Reoperation 1.59 0.97–2.62 1.55 0.57–3.43 1.62 0.56–3.72 1.74 0.43–4.82 1.66 0.64–3.58
Incontinence 2.24 1.03–4.88 1.38 0.11–6.19 0.70 0.09–2.65 1.55 0.34–4.58 1.31 0.38–3.33
AUR 2.89 1.55–5.42 7.21 2.03–18.60 2.27 0.59–6.14 1.21 0.57–2.28 1.41 0.71–2.51
BNC 0.54 0.32–0.90 0.28 0.05–0.91 0.61 0.16–1.64 0.95 0.33–2.17 0.80 0.34–1.62
Blood transfusion 0.14 0.05–0.42 0.05 0.00–0.32 0.04 0.00–0.18 0.19 0.00–1.14 0.04 0.00–0.16
TUR syndrome 0.33 0.01–7.93 0.28 0.05–0.91 0.03 0.00–0.19 0.64 0.00–2.65 0.02 0.00–0.11
UTI 1.17 0.60–2.26 1.00 0.22–2.96 1.03 0.32–2.52 1.75 0.91–3.06 1.66 0.93–2.74
AUR, acute urinary retention; BNC, bladder neck contracture; TUR, transurethral resection; UTI, urinary tract infection.
V
A
L
U
E
IN
H
E
A
L
T
H
1
8
(2
0
1
5
)
3
7
6
–
3
8
6
380
Table 2 – Estimates of unit costs and utilities.
Unit of resource utilization Point
estimate
95%
credible
interval
Distribution Source
Procedure costs
Procedure with overnight stay £2,317 £2307–£2326 Lognormal Elective inpatient, LB25C, TURP without CC,
reference costs
Procedure as day case £1,097 £1025–£1175 Lognormal Day case, LB25C, TURP without CC,
reference costs
% of TURPs as day case 2.97% 2.74%–3.19% Beta TURP without CC, reference costs
Loop
Monopolar £50 £40–£60 Hospital information
Bipolar £180 Hospital information
Fiber £550 Hospital information
Average length of stay with TURP 4.09 3.64–4.54 Normal GOLIATH
Average length of stay with PVP 2.94 2.52–3.37 Normal GOLIATH
Costs of complications (£)
Incontinence, monthly 108 82–134 Triangular Update of NICE Guideline 2010
Bladder pressure test 147 112–182 Lognormal Outpatient procedures, LB42A, reference
costs
Blood transfusion 736 561–911 Triangular Update of NICE Guideline 2010
1-d hospital stay 296 226–367 Lognormal Excess bed day, elective inpatient, LB25C,
reference costs
Outpatient attendance 94 72–116 Lognormal Consultant led follow-up, 101, urology,
reference costs
Artiﬁcial sphincter 5005 3816–6193 Lognormal Elective inpatient, LB21Z, reference costs
1-d high dependency unit 631 481–781 Lognormal Critical care services - XC07Z, adult critical
care, reference costs
No remission, monthly 26 20–33 Triangular Update of NICE Guideline 2010
Loop (electrode) 60 46–74 Uniform Hospital information
Decrease in efﬁcacy second
procedure (%)
25 0.00–50.00 Triangular Lourenco et al. [5]
10-y relapse rate (%) 8 7.50–8.50 Triangular Lourenco et al. [5]
Length of stay
Transurethral resection syndrome 2.5 2–3 Uniform Expert opinion
Laser therapy 2.6 2–3 Negative binomial UK data from GOLIATH
TURP 4 3–5 Negative binomial UK data from GOLIATH
Utilities
No remission 0.94 0.92–0.96 Beta Lourenco et al. [5]
Incontinence 0.89 0.88–0.91 Beta Lourenco et al. [5]
Bladder neck contracture 0.95 0.95–0.96 Beta Lourenco et al. [5]
Acute urinary retention 0.89 0.87–0.92 Beta Lourenco et al. [5]
Transurethral resection syndrome 0.81 0.77–0.85 Beta Lourenco et al. [5]
Urinary tract infection 0.93 0.92–0.94 Beta Lourenco et al. [5]
CC, complication; NICE, National Institute for Health and Care Excellence; PVP, photoselective vaporization of the prostate; TURP,
transurethral resection of the prostate.
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scrutinizing underlying data. Horasanli et al. [13] report seven
reoperations after PVP and zero after TURP. Al-Ansari et al. [16]
report six redo PVP after PVP and one redo after TURP. Within the
experience of the clinical authors, both results may be inter-
preted as reﬂecting an imbalance in surgeon experience between
PVP and TURP and thus noninformative for capturing routine
practice. As a type of sensitivity analysis, one may calculate the
results when omitting these trials from the analysis. This
decreases the risk ratio for repeat operations from 1.66 (0.64–
3.58) to 1.38 (0.51–3.04). In that case, the probability of being more
effective increases from 25.05% to 30.10% and the probability of
an acceptable cost-effectiveness ratio with a £20,000 threshold
increases from 25.45% to 30.00%.
From the most recent data included in “Informed GOLIATH,”
the additional costs are estimated at £130 and the probability of
cost saving is estimated at 20%. This is estimated with 16% ofpatients with PVP as a day case and 2.97% for TURP. When the
percentage of PVP day cases is increased to 32%, as strongly
supported by “time to stable health status o 24 hours” [9], of
more than 70% of the patients with PVP in the United Kingdom,
PVP and TURP show equal costs.Discussion
At the turn of the 21st century, PVP therapy using an 80-W
GreenLight laser system appeared to be a promising new techni-
que for the treatment of symptomatic BPO, resulting in reduced
catheterization times, hospitalization, and the possibility of day-
case surgery. It also offered high-risk patients a viable surgical
alternative to the standard-of-care TURP.
The 2008 HTA concluded that PVP was unlikely to be cost-
effective and the subsequent 2010 NICE directive, with no new
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Fig. 2 – Days in hospital (GOLIATH). PVP, photoselective vaporization of the prostate. (Color version of ﬁgure appears online.)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 7 6 – 3 8 6382cost-effectiveness analysis despite an updated meta-analysis,
suggested limiting PVP in the National Health Service to con-
trolled research settings only. It may be noted that this was
mainly based on the combination of a baseline estimate of
incontinence after laser therapy of 17.51%, which resulted after
multiplying the estimated baseline rate of 7.8% with an estimated
relative risk of 2.34. This ﬁgure—which was used in the calcu-
lations—is in contrast with the average estimate of incontinence
in the trials, which was 5.88%. Moreover, the baseline risk as well
as the risk ratio was affected by the inclusion of a Dutch trial that
registered rates of incontinence of 14/45 after PVP and 4/50 after
TURP. Although these ﬁgures suggest a signiﬁcant difference, the
text surrounding them does not and the abstract of this trial
states: “No clinically relevant differences were found between
these modalities.” This is probably also the reason why the
incontinence data from this trial were excluded from the 2010meta-analysis and this explains the decrease in the risk ratio
from a rather signiﬁcant 2.24 to a rather uncertain 1.38.
A restriction of use may, nevertheless, have been the right
advice in 2008— considering that there was only one RCT for PVP
in its most recent form (Bouchier et al. [8]). Interpretations and
calculations, however, suggested too much certainty. Our calcu-
lations show that if the 2010 meta-analysis would have been
used for a reevaluation of costs and effects, there would have
been a lot less superﬂuous certainty. It would still point into a
negative direction, but one might wonder whether the conclu-
sions would have been milder and would have kept PVP usage at
a higher rate than it has been within the United Kingdom over
the last few years.
In spite of the UK position, GreenLight laser development
continued and the 120-W high performance system (HPS) version
was developed in other countries. The GOLIATH RCT comparing
Table 3 – Baseline results.
2008 meta-analysis 2010 meta-analysis
(80 W)
120-W informed GOLIATH (180 W) GOLIATH (180 W)
informed
Outcome TURP Laser Diff TURP Laser Diff TURP Laser Diff TURP Laser Diff TURP Laser Diff
Years without symptoms 8.51 7.53 0.99 9.17 9.03 0.13 9.29 9.26 0.03 9.06 8.82 0.24 9.10 8.97 0.12
Years without incontinence 8.74 7.81 0.93 9.43 9.38 0.04 9.45 9.48 0.03 9.25 9.09 0.16 9.29 9.21 0.08
Complications (%)
AUR 4.56 13.20 0.09 1.63 11.83 0.10 4.77 10.88 0.06 10.00 12.15 0.02 8.80 12.41 0.04
BNC 6.45 3.48 0.03 6.47 1.82 0.05 7.69 4.67 0.03 7.01 6.69 0.00 7.46 5.98 0.01
Blood transfusion 8.36 1.16 0.07 3.71 0.19 0.04 4.83 0.21 0.05 1.64 0.32 0.01 2.47 0.10 0.02
TUR syndrome 2.10 0.70 0.01 6.47 1.82 0.05 2.73 0.09 0.03 0.38 0.25 0.00 1.04 0.02 0.01
UTI 7.39 8.62 0.01 7.71 7.75 0.00 7.25 7.47 0.00 10.99 19.26 0.08 10.94 18.22 0.07
QALYs 9.72 9.60 0.11 9.79 9.78 0.01 9.80 9.80 0.00 9.78 9.75 0.03 9.78 9.77 0.01
Lower 95% limit 9.71 9.41 0.31 9.76 9.72 0.05 9.78 9.76 0.03 9.75 9.69 0.13 9.73 9.62 0.07
Upper 95% limit 9.75 9.72 0.01 9.81 9.81 0.01 9.82 9.82 0.02 9.80 9.80 0.03 9.81 9.80 0.02
Costs of initial procedures
(£)
2,283 2,347 63 2,283 2,347 63 2,283 2,347 63 2,283 2,347 63 2,403 2,455 51
Costs due to complications
(£)
319 300 20 287 249 38 331 287 44 342 358 17 359 350 9
Repeat procedures (£) 290 291 1 313 348 35 285 309 24 288 315 27 306 322 16
Incontinence (£) 334 712 377 55 71 16 45 33 12 128 193 65 111 144 32
Lack of remission (£) 111 180 69 95 129 34 60 79 19 76 111 35 76 95 19
Costs (£) 3,338 3,829 491 3,033 3,144 111 3,004 3,054 50 3,117 3,324 207 3,256 3,365 109
Lower 95% limit 3,196 3,269 21 2,910 2,818 315 3,074 3,003 373 2,858 2,656 223 2,801 2,622 204
Upper 95% limit 3,337 4,556 1,286 3,346 3,912 £595 3,427 3,805 £489 3,253 3,722 702 3,263 3,524 504
AUR, acute urinary retention; BNC, bladder neck contracture; Diff, difference; QALYs, quality-adjusted life-years; TUR, transurethral resection; TURP, transurethral resection of the prostate; UTI,
urinary tract infection.
V
A
L
U
E
IN
H
E
A
L
T
H
1
8
(2
0
1
5
)
3
7
6
–
3
8
6
383
-2500
-2000
-1500
-1000
-500
0
500
1000
1500
2000
2500
-0.4 -0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4
Co
st
s 
pe
r 
pa
e
nt
Co
st
s 
pe
r 
pa
e
nt
QALYs
-2500
-2000
-1500
-1000
-500
0
500
1000
1500
2000
2500
-0.4 -0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4
QALYs
Fig. 3 – Costs and effects based on 2008 and 2010 meta-analyses. QALYs, quality-adjusted life-years. (Color version of ﬁgure
appears online.)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 7 6 – 3 8 6384the 180-W PVP to TURP for relatively low risk/standardized
patient selection with symptomatic BPO concludes noninferiority
compared with TURP at 6-month follow-up.
When confronted with the problem, a negative study in
2008, continuous developments in time, and at the end, the
GOLIATH study, a Bayesian approach sounded attractive. This
study shows that this may not be as straightforward. Both
treatments under consideration have developed. PVP now has a
more efﬁcient ﬁber delivery system and 100% more power.
Similarly, TURP can now be performed using bipolar technology
in saline irrigation. Even with this knowledge, no clear trends are
found. This may be due to not only patient selection but also-2500
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Fig. 4 – Costs and effects with different sources of information a
version of ﬁgure appears online.)surgeon experience (e.g., Horasanli et al. [13]): The low rate of
adverse events for TURP in GOLIATH (transfusion rates 0.75% vs.
expected 2.9% [9]) was achieved through careful patient selection
and surgery by experienced consultant surgeons only. In con-
trast, individual surgical experience with PVP varied from 10 to
500 cases. Despite this, PVP was shown to be noninferior to TURP.
Such considerations might need to be captured in the priors
considering the various parameters and further study may be
needed to do so.
With respect to patient selection, it may also be noted that the
GOLIATH study and earlier studies have been carried out in
patients in whom TURP is an option. This excludes patients withCo
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bout effectiveness. QALYs, quality-adjusted life-years. (Color
Table 4 – CE results.
Effectiveness Costs 2008
meta-
analysis
(80 W)
2010
meta-
analysis
(80 W)
120-W
informed
by 80 W
GOLIATH
(180 W)
GOLIATH
(180 W)
informed
Less effective More expensive 96.95 55.25 31.70 64.25 60.90
Less expensive 1.75 20.00 12.00 10.55 9.00
CE ratio 4 £20,000 0.15 8.50 6.35 2.70 9.00
CE ratio 4 £30,000 0.15 6.90 4.95 2.15 9.00
More effective More expensive
CE ratio o £20,000 0.40 4.20 11.30 7.35 9.75
CE ratio o £30,000 0.60 5.10 13.10 9.00 11.90
Less expensive 0.50 15.75 35.05 11.60 11.00
Acceptable At a threshold of £20,000 1.05 28.45 52.70 21.65 29.75
At a threshold of £30,000 1.25 27.75 53.10 22.75 31.90
Note. All values are in %.
CE, cost-effectiveness.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 7 6 – 3 8 6 385multiple comorbidities, a group for whom PVP is a real alter-
native. This may need a different analysis but will likely be cost-
effective (given the acceptance of TURP as an intervention in
these patients).
The QALY analysis within this comparison has copied the
approach as followed in 2008. The results still show a favorable
albeit nonsigniﬁcant outcome for TURP. Here other aspects,
such as the signiﬁcant difference in “time to stable health status
o 24 hours,” may enter the equation. Moreover, although day-
case treatment has not been within the remit of GOLIATH, 70%
of the UK patients had “time to stable health statuso 24 hours.”
This potential convenience for both patients and hospital may
also need consideration. It is estimated that when more than
32% of the cases can be treated as a day case, savings can be
expected. In addition, one might consider the beneﬁts this has
in the loss of working days or time to return to daily activities.
Finally, one may want to consider that the analysis as presented
here does not include the heterogeneity of the patient popula-
tion as well as differences in treatment setting. The analysis
suggests a one-size-ﬁts-all-situations approach and this is
unlikely to apply. Especially with TURP, some patients are
predictably at a higher risk of some adverse events and con-
sequently clinicians may—by careful selection—optimize the
balance between costs and effects. The biggest beneﬁts may be
in patients for whom TURP is too risky, patients who did not
enter the trials. The GOLIATH study, as well as earlier studies,
has been carried out in patients in whom TURP is an option.
This excludes patients with multiple comorbidities, a group for
whom PVP is a real alternative. Starting from the results of the
analysis presented here, it is envisaged that if one accepts TURP
as an intervention in those patients, PVP will likely be cost-
effective. Naturally, this will need further substance and the
model as presented here might be used to further deﬁne what
information exactly would be needed [21–29].Conclusions
Caution is needed in the use and interpretation of meta-
analyses that consider the efﬁcacy of procedures that evolve in
time such as PVP and—to a lesser extent—TURP. The current
evidence suggests that over the last 10 years PVP has almost
caught up with TURP. The differences in symptom score are now
small, albeit still in favor of TURP. Differences in convenienceare evidently in favor of PVP. Moreover, although the costs—as
assessed in the GOLIATH trial—are almost equal, PVP can
easily be carried out as a day case and when organized as
such, it is expected to lead to considerable savings. The current
restrictions on the use of PVP need to be reevaluated in light of
these data.Supplemental Materials
Supplemental material accompanying this article can be found in
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